Distinguished in Purine Nucleoside Phosphorylase Deficiency

Renzo Guerrini

Florence, IT 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Purine Nucleoside Phosphorylase Deficiency
Florence, IT 
OverviewLocationsClinical Research

Overview

Renzo Guerrini practices in Florence, Italy. Mr. Guerrini is rated as a Distinguished expert by MediFind in the treatment of Purine Nucleoside Phosphorylase Deficiency. His top areas of expertise are Myoclonic Epilepsy, West Syndrome, Epilepsy with Myoclonic-Atonic Seizures, Cortical Dysplasia, and Deep Brain Stimulation.

His clinical research consists of co-authoring 525 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Purine Nucleoside Phosphorylase Deficiency.

Gender
Male

Locations

Florence, Italy
Other Locations
Sesto Fiorentino, Italy
Meyen, Italy
Sesto San Giovanni, 50019, Italy
Pisa, Italy
Ferrara, Italy
Verona, Italy
Sapienza, Italy
Milan, Italy
Viale, 50139, Italy
Via Dei Giacinti 2, Pisa, Calambrone, 56128, Italy
Genoa, Italy
Bologna, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
View 3 Less Clinical Trials

522 Total Publications

Changes in Gray Matter Morphology and White Matter Microstructure Across the Adult Lifespan in People With Temporal Lobe Epilepsy.
Changes in Gray Matter Morphology and White Matter Microstructure Across the Adult Lifespan in People With Temporal Lobe Epilepsy.
Journal: Neurology
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guerrini's expertise for a condition
ConditionClose
View All 18 Elite Conditions
View All 16 Distinguished Conditions
View All 30 Advanced Conditions
View All 110 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile